Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Acetium capsule prevents the exposure to carcinogenic acetaldehyde in patients with atrophy of the stomach mucosa


Posted on: 08 Nov 16

Biohit Oyj Press Release November 8, 2016 at 09:30 am local time (EET)


New scientific evidence on Acetium capsule has been obtained. A collaborative study with Uppsala University shows that Acetium capsule prevents acetaldehyde exposure in patients suffering from the atrophy of the stomach mucosa (atrophic gastritis) caused by Helicobacter pylori infection. The scientific report has recently been published in Scandinavian Journal of Gastroenterology.

Acetaldehyde associated with alcohol consumption is a group 1 human carcinogen implicated in the pathogenesis of gastric cancer. Atrophic gastritis leads to acid-free stomach that associates with enhanced exposure of gastric mucosa to acetaldehyde and increased risk of gastric cancer. Acetium capsule contains fully safe amino acid, L-cysteine that releases slowly in the stomach and binds acetaldehyde into a harmless compound.

The acetaldehyde-binding effect of Acetium capsule is long-lasting

In the study, the acetaldehyde concentration in the stomach of the patients with Helicobacter pylori associated acid-free stomach was reduced with Acetium-capsule after consuming alcohol. The main new finding of the study was that L-cysteine releasing slowly from Acetium capsule remains in the stomach for several hours and binds effectively (on average 68%) alcohol-derived acetaldehyde into a harmless MTCA-compound (see the Scientific report).

Professor Per Hellström, Uppsala University: ‘Stomach cancer is the fifth most common malignancy worldwide with the third highest mortality. Because of the poor prognosis of gastric cancer, preventive measures are vital. Particularly, the detection of the risk groups and precancerous conditions is important. Atrophic gastritis associating acid-free stomach is the most important independent risk factor for gastric cancer. Our next goal will be to show that disease development can be prevented.’

Professor Kari Syrjänen, Chief Medical Director, Biohit Oyj: ‘The study confirms previous results on the efficacy of Acetium capsule as the eliminator of acetaldehyde in an acid-free stomach caused either by atrophic gastritis or acid suppressive drugs. The presence of Helicobacter pylori and acid free stomach (atrophic gastritis) was confirmed with GastroPanel® test. GastroPanel® test and Acetium capsule are inventions aimed to improve patient safety and to achieve marked health economical savings.'

1. www.biohithealthcare.com/additional-information

2. www.gastropanel.com/decision-makers/screening-model

3. http://www.biohithealthcare.com/limitations-of-helicobacter-pylori-diagnostics

4. Linderborg K et al, Reducing carcinogenic acetaldehyde exposure in the achlorhydric stomach with cysteine. Alcohol Clin Exp Res 2011;35: 516-522.

5. Maejima R et al Effects of ALDH2 genotype, PPI treatment and L-cysteine on carcinogenic acetaldehyde in gastric juice and saliva after intragastric alcohol administration. PLOS ONE |DOI: 10.1371/journal.pone.0120397  April 1,2015

6. Jeong Soo Ahn et al. Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies. World J Gastroenterol 2013 April 28; 19(16): 2560-2568.

 

Artikkeli: Slow-release L-cysteine capsule prevents gastric mucosa exposure to carcinogenic acetaldehyde: results of a randomized single-blinded, cross-over study of Helicobacter-associated atrophic gastritis. Per M. Hellström, Panu Hendolin, Pertti Kaihovaara, Leif Kronberg, Axel Meierjohann, Anders Millerhovf, Lea Paloheimo, Heidi Sundelin, Kari Syrjänen, Dominic-Luc Webb & Mikko Salaspuro. Scandinavian Journal of Gastroenterology  ISSN: 0036-5521 (Print) 1501-7708 (Online) Journal homepage: http://www.tandfonline.com/doi/full/10.1080/00365521.2016.1249403

   

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
www.biohithealthcare.com/additional-information
www.acetium.com

 

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

GlobeNewswire
globenewswire.com

Last updated on: 08/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.